DBV Technologies S.A. DBVT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
39/100
Developing

Ranked against 712 peers in Biotechnology

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated … Full DBVT analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.70), suggesting sticky customer base.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.28), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where DBVT ranks in Biotechnology

DBV Technologies S.A. ranks #384 of 713 scored companies in Biotechnology by moat score — the top 54%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
380 Lyra Therapeutics, Inc. LYRA 39/100 Developing
381 Veru Inc. VERU 39/100 Developing
382 NRX Pharmaceuticals, Inc. NRXP 39/100 Developing
383 NRx Pharmaceuticals, Inc. NRXPW 39/100 Developing
384 DBV Technologies S.A. DBVT 39/100 Developing
385 Lipocine Inc. LPCN 38/100 Developing
386 Acumen Pharmaceuticals, Inc. ABOS 38/100 Developing
387 Replimune Group, Inc. REPL 38/100 Developing
388 Tectonic Therapeutic, Inc. TECX 38/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How DBVT scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 70 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 29 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 33 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding DBVT's moat

What is DBV Technologies S.A.'s moat score?

DBV Technologies S.A. (DBVT) scores 39 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #384 of 713 scored companies in Biotechnology, the top 54%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (70/100) and its weakest is Capital Efficiency (29/100).

How does DBV Technologies S.A. compare with other Biotechnology companies?

DBV Technologies S.A. ranks #384 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are NRx Pharmaceuticals, Inc. (NRXPW) at 39 just above it and Lipocine Inc. (LPCN) at 38 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is DBV Technologies S.A. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for DBV Technologies S.A.?

The Corporate Default template measures 6 defenses, and DBVT scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (70), Capital Efficiency (29), Resilience (33), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000